Diabetes type 2. Insulin-dependent diabetes mellitus, Non-insulin-dependent diabetes mellitus, Malnutrition-related diabetes mellitus, Other specified diabetes mellitus, Unspecified diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group 1: Every day, members of the intervention group 1 receive three 450 mg oral capsules of the aqueous extract of rhubarb for six weeks which is made at School of Pharm
Treatment - Drugs
Placebo
Intervention group 1: Every day, members of the intervention group 1 receive three 450 mg oral capsules of the aqueous extract of rhubarb for six weeks which is made at School of Pharmacy, Shahid Behe
control group: Every day, members of the control group receive three 450 mg oral capsules of the placebo for six weeks which is made at School of Pharmacy, Shahid Beheshti University of Medical Scienc
Intervention group 2: Every day, members of the intervention group 1 receive three 450 mg oral capsules of the alcoholic extract of rhubarb for six weeks which is made at School of Pharmacy, Shahid Be
Sponsors
Vice Chancellor for research, Iran University of Medical Sciences,
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 30-60-year old patients with fasting blood glucose of greater than 126 mg/dl are included in the project. Exclusion criteria: Patients with hyperglycemia caused by diseases other than diabetes, patients suffering from liver, thyroid and kidney diseases, patients being treated with insulin, taking ß-blockers and lipid-lowering drugs, consuming alcoholic drinks, having severe, acute, active infectious diseases when blood samples are taken, and patients who are hospitalized during the study are excluded from the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body Mass Index. Timepoint: Before and 6 weeks after intervention. Method of measurement: SECA,Kilogram per meter Square.;Malondialdehyde. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: Spectrophotometry, mmol/L.;High sensitivity c-reactive protein. Timepoint: Before and 6 weeks after intervention. Method of measurement: immunoturbidimetry, mg/dl.;Fasting Blood Sugar. Timepoint: Before and 6 weeks after intervention. Method of measurement: glucose oxsidase , mg/dl.;Apolipoprotein B. Timepoint: Before and 6 weeks after intervention. Method of measurement: immunoturbidimetry, mg/dl.;Apolipoprotein A1. Timepoint: Before and 6 weeks after intervention. Method of measurement: immunoturbidimetry, mg/dl.;Insulin level. Timepoint: Before and 6 weeks after intervention. Method of measurement: enzymatic, mg/dl. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Pressure. Timepoint: Before and 6 weeks after intervention. Method of measurement: Mercury Sphygmomanometer, mmHg. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzad Shidfar
Iran University of Medical Sciences
Outcome results
None listed